FY2025 Earnings Forecast for DNTH Issued By Lifesci Capital

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) – Investment analysts at Lifesci Capital boosted their FY2025 EPS estimates for Dianthus Therapeutics in a research note issued to investors on Wednesday, March 12th. Lifesci Capital analyst R. Katkhuda now anticipates that the company will earn ($2.50) per share for the year, up from their prior estimate of ($2.53). The consensus estimate for Dianthus Therapeutics’ current full-year earnings is ($2.61) per share.

Dianthus Therapeutics (NASDAQ:DNTH) last released its earnings results on Tuesday, March 11th. The company reported ($0.81) EPS for the quarter, topping analysts’ consensus estimates of ($0.85) by $0.04. Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. The business had revenue of $1.33 million during the quarter, compared to analysts’ expectations of $1.40 million.

DNTH has been the subject of several other research reports. TD Cowen started coverage on shares of Dianthus Therapeutics in a research note on Friday, December 20th. They issued a “buy” rating for the company. Wedbush restated an “outperform” rating and issued a $36.00 price objective on shares of Dianthus Therapeutics in a report on Wednesday. HC Wainwright restated a “buy” rating and issued a $40.00 price objective on shares of Dianthus Therapeutics in a report on Wednesday. Raymond James upgraded shares of Dianthus Therapeutics to a “moderate buy” rating in a report on Thursday, December 12th. Finally, Guggenheim reiterated a “buy” rating and set a $84.00 target price on shares of Dianthus Therapeutics in a report on Wednesday. Eight equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, Dianthus Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $52.14.

Dianthus Therapeutics Trading Up 0.2 %

Shares of NASDAQ DNTH opened at $21.33 on Friday. Dianthus Therapeutics has a 12-month low of $18.13 and a 12-month high of $33.77. The stock has a market cap of $631.30 million, a PE ratio of -8.53 and a beta of 1.82. The company has a 50-day moving average of $22.61 and a 200 day moving average of $24.92.

Hedge Funds Weigh In On Dianthus Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in DNTH. TCG Crossover Management LLC purchased a new stake in shares of Dianthus Therapeutics during the fourth quarter worth about $32,735,000. Braidwell LP grew its stake in Dianthus Therapeutics by 144.4% during the fourth quarter. Braidwell LP now owns 1,206,589 shares of the company’s stock worth $26,304,000 after buying an additional 712,902 shares during the period. Vestal Point Capital LP grew its stake in Dianthus Therapeutics by 172.2% during the fourth quarter. Vestal Point Capital LP now owns 1,075,000 shares of the company’s stock worth $23,435,000 after buying an additional 680,000 shares during the period. State Street Corp grew its stake in Dianthus Therapeutics by 101.4% during the third quarter. State Street Corp now owns 821,131 shares of the company’s stock worth $22,483,000 after buying an additional 413,425 shares during the period. Finally, Octagon Capital Advisors LP grew its stake in Dianthus Therapeutics by 20.8% during the fourth quarter. Octagon Capital Advisors LP now owns 2,110,167 shares of the company’s stock worth $46,002,000 after buying an additional 363,500 shares during the period. Institutional investors and hedge funds own 47.53% of the company’s stock.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.